Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating multiple sclerosis with monoclonal antibodies: the cons.

R E Champlin1

  • 1Department of Medicine, UCLA School of Medicine 90024.

Neurology
|July 1, 1988
PubMed
Summary

Monoclonal antibodies (MAbs) show promise for multiple sclerosis (MS) treatment but face limitations. Current murine MAb therapies are often infeasible for long-term use due to immune responses and lack of cell lysis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Blood·2020
Same author

HLA-mismatched bone marrow transplantation in severe aplastic anemia.

Bone marrow transplantation·2017
Same author

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Leukemia·2017
Same author

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Bone marrow transplantation·2016
Same author

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Leukemia·2016
Same author

Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.

Bone marrow transplantation·2016

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Monoclonal antibodies (MAbs) represent a promising therapeutic avenue for multiple sclerosis (MS).
  • Current clinical applications of MAbs in MS are hindered by significant limitations.
  • Murine-derived MAbs are the primary preparations currently available for MS treatment.

Purpose of the Study:

  • To evaluate the clinical efficacy and limitations of monoclonal antibody (MAb) therapy in multiple sclerosis (MS).
  • To identify key challenges associated with the current use of murine MAbs in MS management.
  • To underscore the need for further investigation into MAb applications for MS.

Main Methods:

  • Review of clinical studies on monoclonal antibody (MAb) infusion in multiple sclerosis (MS) patients.

Related Experiment Videos

  • Analysis of immunological responses, specifically antimurine antibody production.
  • Assessment of MAb lytic activity and target antigen modulation in the context of MS.

    • Main Results:

    • Infusion of murine MAbs frequently elicits an antimurine antibody response, compromising long-term therapeutic feasibility.
    • Most murine MAbs lack sufficient lytic activity against targeted cells in MS.
    • Target antigen modulation leads to the reappearance of functional cells despite ongoing MAb therapy.

    Conclusions:

    • Current murine MAb therapies for MS are limited by immunogenicity and suboptimal efficacy.
    • The development of effective retreatment strategies for chronic MS is crucial and challenged by existing MAb limitations.
    • Randomized, controlled clinical trials are essential to clarify the role and optimize the use of MAbs in MS treatment.